Suppr超能文献

T1期高级别膀胱癌的最佳管理

The optimal management of T1 high-grade bladder cancer.

作者信息

Nepple Kenneth G, O'Donnell Michael A

机构信息

University of Iowa Department of Urology, Iowa City, IA.

出版信息

Can Urol Assoc J. 2009 Dec;3(6 Suppl 4):S188-92.

Abstract

Stage T1Hg bladder cancer should be considered an aggressive and potentially lethal disease. The importance of initial re-resection to identify unrecognized muscle-invasive disease is significant. Most patients with high-risk disease are candidates for initial bladder salvage with intravesical bacillus Calmette-Guerin vaccine for immunotherapy, a procedure with a high survival rate; however, failure of the procedure may result in a guarded prognosis. Even after apparent success, patients should be informed of the risks of the disease progressing to muscle-invasive or metastatic disease and the need for vigilant monitoring. Despite optimal management, a significant number of patients relapse or progress to invasive disease requiring cystectomy. This review provides insight into the optimal management of T1 high-grade bladder cancer.

摘要

T1Hg期膀胱癌应被视为一种侵袭性且可能致命的疾病。初次再次切除以识别未被发现的肌层浸润性疾病非常重要。大多数高危疾病患者适合采用膀胱内卡介苗免疫疗法进行初次膀胱挽救,该方法生存率较高;然而,该方法失败可能导致预后不佳。即使表面上取得成功,也应告知患者疾病进展为肌层浸润性或转移性疾病的风险以及进行密切监测的必要性。尽管进行了最佳管理,仍有相当数量的患者复发或进展为需要膀胱切除术的浸润性疾病。本综述深入探讨了T1高级别膀胱癌的最佳管理方法。

相似文献

1
The optimal management of T1 high-grade bladder cancer.
Can Urol Assoc J. 2009 Dec;3(6 Suppl 4):S188-92.
2
Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations.
Eur Urol. 2018 Nov;74(5):597-608. doi: 10.1016/j.eururo.2018.06.024. Epub 2018 Jul 13.
4
Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Eur Urol Oncol. 2019 May;2(3):286-293. doi: 10.1016/j.euo.2018.08.013. Epub 2018 Sep 10.
5
A risk-stratified approach to the management of high-grade T1 bladder cancer.
Curr Opin Urol. 2018 Nov;28(6):563-569. doi: 10.1097/MOU.0000000000000548.
8
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Eur Urol. 2013 Oct;64(4):639-53. doi: 10.1016/j.eururo.2013.06.003. Epub 2013 Jun 12.

引用本文的文献

1
Metastasis development in non-muscle-invasive bladder cancer.
Nat Rev Urol. 2024 Nov 20. doi: 10.1038/s41585-024-00963-y.
5
Genitourinary Tissue Engineering: Reconstruction and Research Models.
Bioengineering (Basel). 2021 Jul 13;8(7):99. doi: 10.3390/bioengineering8070099.
6
Non-Muscular Invasive Bladder Cancer: Re-envisioning Therapeutic Journey from Traditional to Regenerative Interventions.
Aging Dis. 2021 Jun 1;12(3):868-885. doi: 10.14336/AD.2020.1109. eCollection 2021 Jun.
7
Role of magnetic resonance imaging in tumor staging and follow-up for bladder cancer.
Transl Androl Urol. 2020 Dec;9(6):2890-2907. doi: 10.21037/tau-19-671.
8
Where do urologists stand in the era of novel coronavirus-2019 disease.
Curr Opin Urol. 2020 Jul;30(4):610-616. doi: 10.1097/MOU.0000000000000786.
9
Impact of intravesical therapy for non-muscle invasive bladder cancer on the accuracy of urine cytology.
World J Urol. 2019 Oct;37(10):2051-2058. doi: 10.1007/s00345-018-02624-3. Epub 2019 Jan 23.

本文引用的文献

3
Combination of BCG and interferon intravesical immunotherapy: an update.
World J Urol. 2009 Jun;27(3):343-6. doi: 10.1007/s00345-009-0429-6. Epub 2009 May 29.
5
Clinical outcome of chemoradiotherapy for T1G3 bladder cancer.
Int J Urol. 2008 Aug;15(8):747-50. doi: 10.1111/j.1442-2042.2008.02077.x.
6
Invasive T1 bladder cancer: indications and rationale for radical cystectomy.
BJU Int. 2008 Aug;102(3):270-5. doi: 10.1111/j.1464-410X.2008.07743.x. Epub 2008 May 20.
10
The best treatment for high-grade T1 bladder cancer is cystectomy.
Urol Oncol. 2007 Nov-Dec;25(6):523-5. doi: 10.1016/j.urolonc.2007.05.023.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验